Brief: Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren’S Disease
10/06/2025 23:14
June 10 (Reuters) - argenx SE ARGX.BR: ARGENX PRESENTS NEW EFGARTIGIMOD DATA AT EULAR 2025 HIGHLIGHTING POSITIVE PHASE 2 PROOF-OF-CONCEPT RESULTS IN MYOSITIS AND SJOGREN’S DISEASE Source text: ID:nGNX7mQV3G Further company coverage: ARGX.BR (((( Reuters.briefs@thomsonreuters.com ;));))